{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "48-year-old man with a 28-year history of smoking presented with abnormal shadow in left lung. Diagnosed with lung adenocarcinoma in the left upper lobe with left adrenal metastasis (cT2aN2M1b, Stage IVA) with PD-L1 tumor proportion score of 1-49%.",
        "clinical_data": {
          "social_history": [
            {
              "category": "smoking",
              "status": "past",
              "description": "28-year history of smoking"
            }
          ],
          "diagnoses": [
            {
              "code": "C34.9",
              "label": "Lung adenocarcinoma",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C79.6",
              "label": "Metastatic cancer of adrenal gland",
              "status": "active",
              "onset_date": null
            }
          ],
          "imaging": [
            {
              "type": "Shadow",
              "body_part": "Left lung",
              "modality": "X-ray",
              "finding": "abnormal shadow",
              "impression": "abnormal shadow",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Received four cycles of cisplatin, pemetrexed and bevacizumab as first-line therapy, followed by pemetrexed and bevacizumab as maintenance therapy for two cycles.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0008893",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1637444",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1263434",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1637444",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1263434",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 3,
        "content": "Increase in size of primary lung lesion observed. Treated with pembrolizumab (200 mg/kg every 3 weeks) as second-line therapy.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0000970",
              "dosage": "200 mg/kg",
              "frequency": "every 3 weeks",
              "modality": "IV",
              "start_date": null,
              "end_date": null,
              "indication": "Lung lesion"
            }
          ],
          "diagnoses": [
            {
              "code": "Lung lesion",
              "label": "Lung lesion",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 5,
        "content": "Eleven days after the second administration of pembrolizumab, patient presented with fever and progressive fatigue and was admitted to hospital. Conjunctiva and skin were icteric. Laboratory examinations revealed: AST 413 U/L, ALT 175 U/L, ALP 1,033 U/L, \u03b3-GTP 649 U/L, total bilirubin 5.4 mg/dL (including 3.9 mg/dL direct bilirubin), platelets 27,000 /\u03bcL and fibrin degradation products 61.3 \u03bcg/mL. Viral etiology (hepatitis B and C virus or cytomegalovirus) and autoimmune origin (antinuclear and antimitochondrial antibodies) were not proven.",
        "clinical_data": {
          "labs": [
            {
              "test": "Aspartate Aminotransferase Measurement",
              "value": "413",
              "unit": "U/L",
              "flag": "abnormal"
            },
            {
              "test": "Alanine Aminotransferase Measurement",
              "value": "175",
              "unit": "U/L",
              "flag": "abnormal"
            },
            {
              "test": "Alkaline Phosphatase Measurement",
              "value": "1033",
              "unit": "U/L",
              "flag": "abnormal"
            },
            {
              "test": "Gamma-Glutamyl Transferase Measurement",
              "value": "649",
              "unit": "U/L",
              "flag": "abnormal"
            },
            {
              "test": "bilirubin measurement",
              "value": "5.4",
              "unit": "mg/dL",
              "flag": "abnormal"
            },
            {
              "test": "direct bilirubin measurement",
              "value": "3.9",
              "unit": "mg/dL",
              "flag": "abnormal"
            },
            {
              "test": "Platelet count",
              "value": "27000",
              "unit": "/\u03bcL",
              "flag": "abnormal"
            },
            {
              "test": "Fibrin Degradation Products",
              "value": "61.3",
              "unit": "\u03bcg/mL",
              "flag": "abnormal"
            }
          ],
          "HPI": [
            {
              "summary": "Patient presented with fever and progressive fatigue",
              "progression": "progressive"
            }
          ],
          "diagnoses": [
            {
              "code": "C0022116",
              "label": "Fever",
              "status": "active"
            },
            {
              "code": "C0015672",
              "label": "Fatigue",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 6,
        "content": "On admission: Chest X-ray showed a nodular shadow in the left upper lung field. Thoracic computed tomography revealed a 2.6x3.0 cm nodular shadow in the left upper lobe. Enhanced abdominal computed tomography revealed splenomegaly. Abdominal ultrasonography showed a finding suggesting a fatty liver.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Nodular shadow",
              "body_part": "Left upper lung field",
              "modality": "X-ray",
              "finding": "Nodular shadow in the left upper lung field",
              "date": null
            },
            {
              "type": "Nodule",
              "body_part": "Lung",
              "modality": "CT",
              "finding": "2.6x3.0 cm nodular shadow in the left upper lobe",
              "date": null
            },
            {
              "type": "Splenomegaly",
              "body_part": "Spleen",
              "modality": "CT",
              "finding": "Splenomegaly",
              "date": null
            },
            {
              "type": "Fatty liver",
              "body_part": "Liver",
              "modality": "Ultrasound",
              "finding": "Finding suggesting a fatty liver",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 7,
        "content": "Prednisolone 80 mg (1 mg/kg) administered once daily due to suspected drug-induced liver injury caused by pembrolizumab. After prednisolone administration, bilirubin, AST, and ALT decreased, but serum ALP and \u03b3-GTP did not improve.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0032463",
              "dosage": "80 mg (1 mg/kg)",
              "frequency": "once daily",
              "modality": "oral",
              "indication": "drug-induced liver injury"
            },
            {
              "drug": "C4049449",
              "indication": "drug-induced liver injury"
            }
          ],
          "labs": [
            {
              "test": "C0005064",
              "value": "decreased",
              "unit": null,
              "flag": "abnormal"
            },
            {
              "test": "C0004047",
              "value": "decreased",
              "unit": null,
              "flag": "abnormal"
            },
            {
              "test": "C0001758",
              "value": "decreased",
              "unit": null,
              "flag": "abnormal"
            },
            {
              "test": "C0002892",
              "value": "did not improve",
              "unit": null,
              "flag": "abnormal"
            },
            {
              "test": "C0085583",
              "value": "did not improve",
              "unit": null,
              "flag": "abnormal"
            }
          ],
          "diagnoses": [
            {
              "code": "C0235954",
              "label": "Drug-Induced Liver Injury",
              "status": "suspected"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 8,
        "content": "Diagnostic liver biopsy performed due to prolonged biliary tract involvement. Histopathology revealed inflammatory cell infiltration of the portal tract and destruction of the interlobular bile duct, with normal parenchyma architecture.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Liver Biopsy",
              "date": null,
              "location": "liver",
              "outcome": "inflammatory cell infiltration of the portal tract and destruction of the interlobular bile duct, with normal parenchyma architecture"
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "inflammatory cell infiltration of the portal tract",
              "status": "active",
              "onset_date": null
            },
            {
              "code": null,
              "label": "destruction of the interlobular bile duct",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 9,
        "content": "Liver biopsy immunohistopathology showed inflammatory cells represented by CD8+ lymphocytes. Pathology findings suggested cholestatic liver injury.",
        "clinical_data": {
          "labs": [
            {
              "test": "Liver biopsy",
              "finding": "inflammatory cells represented by CD8+ lymphocytes",
              "finding2": "cholestatic liver injury"
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 10,
        "content": "Ursodeoxycholic acid (UDCA) 900 mg daily was commenced after pathological finding was obtained, which led to improvement of biliary tract enzymes.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0041961",
              "dosage": "900 mg",
              "frequency": "daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 11,
        "content": "After 4 weeks of taking prednisolone 80 mg daily, the dosage was tapered to about 10 mg every 2 weeks without any recurrence of hepatitis.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0032444",
              "dosage": "80 mg",
              "frequency": "daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": "hepatitis"
            }
          ]
        }
      }
    },
    {
      "id": "N11",
      "label": "Step 11",
      "customData": {
        "node_id": "K",
        "node_step_index": 12,
        "content": "Primary lesion of the left upper lobe rapidly became enlarged after the improvement of liver injury.",
        "clinical_data": {
          "imaging": [
            {
              "body_part": "Left upper lobe",
              "finding": "Primary lesion enlarged",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N12",
      "label": "Step 12",
      "customData": {
        "node_id": "L",
        "node_step_index": 13,
        "content": "Received docetaxel and ramcirumab as a third-line therapy. General condition quickly worsened due to the progress of lung cancer.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0013093",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "C0024117"
            },
            {
              "drug": "C3150080",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "C0024117"
            }
          ],
          "diagnoses": [
            {
              "code": "C0024117",
              "label": "Lung Cancer",
              "status": "active",
              "onset_date": null
            }
          ],
          "HPI": [
            {
              "summary": "General condition quickly worsened due to the progress of lung cancer.",
              "duration": null,
              "onset": null,
              "progression": "sudden",
              "associated_symptoms": [],
              "alleviating_factors": [],
              "exacerbating_factors": []
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient received first-line therapy for lung adenocarcinoma and adrenal metastasis.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0008893",
            "C1637444",
            "C1263434"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Lung lesion increased in size despite first-line therapy.",
        "transition_event": {
          "trigger_type": "progression",
          "trigger_entities": [
            "Lung lesion"
          ],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Patient developed fever, fatigue, jaundice, thrombocytopenia, and elevated liver enzymes after pembrolizumab administration, suggestive of liver injury.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0022116",
            "C0015672"
          ],
          "change_type": "addition",
          "target_domain": "symptom"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Imaging revealed nodular shadow in the left upper lung field, splenomegaly, and fatty liver.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Prednisolone was administered for suspected drug-induced liver injury. Bilirubin, AST, and ALT decreased, but ALP and \u03b3-GTP did not improve.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0032463"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Liver biopsy performed due to prolonged biliary tract involvement.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [
            "Liver Biopsy"
          ],
          "change_type": "addition",
          "target_domain": "procedure"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "Liver biopsy immunohistopathology showed inflammatory cells represented by CD8+ lymphocytes. Pathology findings suggested cholestatic liver injury.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [],
          "change_type": "reinterpretation",
          "target_domain": "lab"
        }
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Ursodeoxycholic acid (UDCA) was commenced after pathological finding was obtained, which led to improvement of biliary tract enzymes.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0041961"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N9",
      "to": "N10",
      "data": {
        "edge_id": "I_to_J"
      }
    }
  ]
}